Prelude Therapeutics Appoints Katina Dorton to Board

Prelude Therapeutics ( (PRLD) ) has provided an update.

On October 17, 2025, Prelude Therapeutics announced the appointment of Katina Dorton to its Board of Directors, following the resignation of Mardi Dier. Ms. Dorton, who brings over 30 years of experience in finance and healthcare, will serve as Chair of the Audit Committee. Her extensive background in strategic and financial advisory roles is expected to contribute significantly to Prelude’s goals in advancing its precision oncology drug candidates.

The most recent analyst rating on (PRLD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.

Spark’s Take on PRLD Stock

According to Spark, TipRanks’ AI Analyst, PRLD is a Underperform.

Prelude Therapeutics faces significant financial hurdles due to ongoing losses and lack of revenue, which heavily impact its overall score. Technical analysis shows mixed short-term momentum, but long-term weakness persists. The valuation is challenged by a negative P/E ratio and lack of dividends. However, recent corporate developments, including promising clinical results and a solid cash runway, offer some positive aspects, albeit insufficient to offset the broader financial concerns.

To see Spark’s full report on PRLD stock, click here.

More about Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients. Their pipeline includes novel drug candidates such as SMARCA2 and KAT6A degraders, and they are working on next-generation degrader antibody conjugates (Precision ADCs) to enhance precision medicine in oncology.

Average Trading Volume: 217,016

Technical Sentiment Signal: Hold

Current Market Cap: $74.14M

Learn more about PRLD stock on TipRanks’ Stock Analysis page.